Crescent Biopharma Inc (CBIO)
Crescent Biopharma, Inc. is a NASDAQ-listed biotechnology company focused on researching and developing cancer therapy candidates in the United States. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody in Phase 3 clinical testing for solid tumors, as well as CR-002 and CR-003. The company also has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. related to the development and commercialization of oncology therapeutics. Formerly known as GlycoMimetics, Inc., Crescent Biopharma was founded in 2024 and is headquartered in Waltham, Massachusetts.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CBIO
|
$13.34
|
-17.4% Downside
|
Fair
|
$31
|
92.0% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
-3.3x
|
3.0x
|
44.7x
|
500.1 M
|
348 M
|
0.3%
|
42.4%
|
16.7
|
—
|
43.6%
|
